Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous caffeine citrate for prevention of acute kidney injury in preterm neonates
IRCT20260916071079N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of caffeine in acute kidney failure (AKF) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Creatinine. Started Apr 2026; status: completed.
02
Drugs
caffeine
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on IRCT20260916071079N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260916071079N1.